keyword
MENU ▼
Read by QxMD icon Read
search

Anti-VEGF

keyword
https://www.readbyqxmd.com/read/28930884/rate-of-macular-ganglion-cell-inner-plexiform-layer-thinning-in-glaucomatous-eyes-with-vascular-endothelial-growth-factor-inhibition
#1
Won June Lee, Young Kook Kim, Yong Woo Kim, Jin Wook Jeoung, Seok Hwan Kim, Jang Won Heo, Hyeong Gon Yu, Ki Ho Park
PURPOSE: To evaluate the rate of progressive macular ganglion cell-inner plexiform layer (GCIPL) thinning in patients with open-angle glaucoma (OAG) who had been treated with intravitreal anti-vascular endothelial growth factor (VEGF) injection for wet age-related macular degeneration (AMD). METHODS: This study was a retrospective modified case control study with fellow-eye comparison. We enrolled bilateral OAG patients who had been treated with repeated anti-VEGF injections for unilateral wet AMD and followed-up on for a minimum of 24 months by Cirrus high-definition optical coherence tomography (HD-OCT)...
September 19, 2017: Journal of Glaucoma
https://www.readbyqxmd.com/read/28926846/different-clinical-courses-on-long-term-follow-up-of-age-related-macular-degeneration-patients-treated-with-intravitreal-anti-vascular-endothelial-growth-factor-injections
#2
Oded Sagiv, Ofira Zloto, Iris Moroz, Joseph Moisseiev
PURPOSE: To assess the long-term outcome of neovascular age-related macular degeneration (AMD) treated with multiple intravitreal anti-vascular endothelial growth factor (VEGF) injections. METHODS: All patients treated with over 30 intravitreal anti-VEGF injections for neovascular AMD between 2007 and 2014 were retrospectively reviewed. RESULTS: A total of 67 eyes received 2,960 (mean 45 ± 9.1 per eye) anti-VEGF injections. Eyes with good final visual acuity (VA) had better initial VA (p = 0...
September 20, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28924438/central-retinal-vein-occlusion-in-2-patients-using-antipsychotic-drugs
#3
Koichiro Taki, Teruyo Kida, Masanori Fukumoto, Takaki Sato, Hidehiro Oku, Tsunehiko Ikeda
PURPOSE: To report our findings in 2 patients who developed a central retinal vein occlusion (CRVO) and were chronic users of antipsychotic medications. CASE PRESENTATION: Case 1 was a 62-year-old woman who had a sudden reduction of vision in her right eye to 20/2,000. Her fundus showed signs of an impending CRVO with marked macular edema. She had been taking antipsychotic drugs (quetiapine fumarate and risperidone) for about 2 years. She refused anti-VEGF therapy for her macular edema but selected systemic kallidinogenase...
May 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28923916/critical-role-of-caveolin-1-in-ocular-neovascularization-and-multitargeted-antiangiogenic-effects-of-cavtratin-via-jnk
#4
Yida Jiang, Xianchai Lin, Zhongshu Tang, Chunsik Lee, Geng Tian, Yuxiang Du, Xiangke Yin, Xiangrong Ren, Lijuan Huang, Zhimin Ye, Wei Chen, Fan Zhang, Jia Mi, Zhiqin Gao, Shasha Wang, Qishan Chen, Liying Xing, Bin Wang, Yihai Cao, William C Sessa, Rong Ju, Yizhi Liu, Xuri Li
Ocular neovascularization is a devastating pathology of numerous ocular diseases and is a major cause of blindness. Caveolin-1 (Cav-1) plays important roles in the vascular system. However, little is known regarding its function and mechanisms in ocular neovascularization. Here, using comprehensive model systems and a cell permeable peptide of Cav-1, cavtratin, we show that Cav-1 is a critical player in ocular neovascularization. The genetic deletion of Cav-1 exacerbated and cavtratin administration inhibited choroidal and retinal neovascularization...
September 18, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28918027/adeno-associated-viral-vector-mediated-mtor-inhibition-by-short-hairpin-rna-suppresses-laser-induced-choroidal-neovascularization
#5
Tae Kwann Park, Si Hyung Lee, Jun Sub Choi, Seung Kwan Nah, Hee Jong Kim, Ha Yan Park, Heuiran Lee, Steven Hyun Seung Lee, Keerang Park
Choroidal neovascularization (CNV) is the defining characteristic feature of the wet subtype of age-related macular degeneration (AMD) and may result in irreversible blindness. Based on anti-vascular endothelial growth factor (anti-VEGF), the current therapeutic approaches to CNV are fraught with difficulties, and mammalian target of rapamycin (mTOR) has recently been proposed as a possible therapeutic target, although few studies have been conducted. Here, we show that a recombinant adeno-associated virus-delivered mTOR-inhibiting short hairpin RNA (rAAV-mTOR shRNA), which blocks the activity of both mTOR complex 1 and 2, represents a promising therapeutic approach for the treatment of CNV...
September 15, 2017: Molecular Therapy. Nucleic Acids
https://www.readbyqxmd.com/read/28916483/recombinant-humanized-anti-vascular-endothelial-growth-factor-monoclonal-antibody-efficiently-suppresses-laser-induced-choroidal-neovascularization-in-rhesus-monkeys
#6
Wan-Wan Ji, Dong-An Yu, Peng Yang, Peng Fang, Yu-Xia Cao, Hu Li, Ning Xie, Shou-Sheng Yan
Neovascular age-related macular degeneration, characterized by abnormal choroidal neovascularization (CNV), is a major cause of blindness worldwide. Anti-vascular endothelial growth factor (VEGF) antibodies have demonstrated significant efficacy in improving visual acuity. TMAB001 is a new recombinant humanized rabbit anti-VEGF monoclonal antibody. It presents high activities in vitro studies. In the binding affinity assay, TMAB001 exhibited a high binding capability to VEGF with an affinity constant of 10(-11)M...
September 12, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28916115/-retinal-vein-occlusions
#7
REVIEW
A Pierru, J-F Girmens, E Héron, M Paques
Retinal venous occlusions comprise central retinal vein occlusion, hemiretinal vein occlusions, and branch retinal vein occlusions. They are associated with arterial hypertension and glaucoma. Retinal vein occlusions occur more frequently in males, at a median age of 55. The pathogenesis of retinal venous occlusions remains obscure. The clinical presentation of the disease is variable. In most cases, there is a unilateral visual loss over days with a painless, white and quiet eye. However, retinal venous occlusions may also present as an abrupt and profound loss of vision, or be asymptomatic...
September 12, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28914194/diabetic-retinopathy-recent-updates-on-different-biomarkers-and-some-therapeutic-agents
#8
Amjad Ali Khan, Arshad Husain Rahmani, Yousef Homood Aldebasi
BACKGROUND: Diabetic Retinopathy is a leading cause of sight-threatening complication, which occurs due to a number of physiological and metabolic abnormalities during later stages of diabetes. Many of these abnormal changes are consistent with altered oxidative stress, inflammation, genetic set up, advanced glycation end products, and hematological changes. So the altered levels of different biomolecules related to these changes serve as important biomarkers to assess better evaluation and early treatment of this disease...
September 15, 2017: Current Diabetes Reviews
https://www.readbyqxmd.com/read/28912141/macropinocytosis-of-bevacizumab-by%C3%A2-glioblastoma-cells-in-the-perivascular-niche-affects-their-survival
#9
Gaëlle M Müller-Greven, Cathleen Carlin, Monica E Burgett, Manmeet Singh Ahluwalia, Adam Lauko, Amy S Nowacki, Cameron J Herting, Maha A Qadan, Markus Bredel, Steven A Toms, Justin D Lathia, Dolores Hambardzumyan, Jann N Sarkaria, Petra Hamerlik, Candece L Gladson
PURPOSE: Bevacizumab, a humanized monoclonal antibody to VEGF, is used routinely in the treatment of patients with recurrent glioblastoma (GBM). However, very little is known regarding the effects of bevacizumab on the cells in the perivascular space in tumors. EXPERIMENTAL DESIGN: Established orthotopic xenograft and syngeneic models of GBM were used to determine entry of monoclonal anti-VEGF-A into, and uptake by cells in, the perivascular space. Based on the results, we examined CD133+ cells derived from GBM tumors in vitro...
September 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28911884/anti-vegf-treatment-improves-neurological-function-in-tumors-of-the-nervous-system
#10
REVIEW
Na Zhang, Jie Chen, Gino Ferraro, Limeng Wu, Meenal Datta, Rakesh K Jain, Scott R Plotkin, Anat Stemmer-Rachamimov, Lei Xu
Research of various diseases of the nervous system has shown that VEGF has direct neuroprotective effects in the central and peripheral nervous systems, and indirect effects on improving neuronal vessel perfusion which leads to nerve protection. In the tumors of the nervous system, VEGF plays a critical role in tumor angiogenesis and tumor progression. The effect of anti-VEGF treatment on nerve protection and function has been recently reported - by normalizing the tumor vasculature, anti-VEGF treatment is able to relieve nerve edema and deliver oxygen more efficiently into the nerve, thus reducing nerve damage and improving nerve function...
September 11, 2017: Experimental Neurology
https://www.readbyqxmd.com/read/28905539/new-treatment-modalities-for-geographic-atrophy
#11
Rathika Kandasamy, Sanjeewa Wickremasinghe, Robyn Guymer
Age-related macular degeneration (AMD) is a significant cause of global visual morbidity and is projected to affect 288 million people by the year 2040. The advent of treatment with anti‒vascular endothelial growth factor (anti-VEGF) drugs has revolutionized the treatment of neovascular AMD (nAMD) but there have been no similar breakthroughs for the treatment of geographic atrophy (GA) to retard its progression. The advancements in imaging and new understanding of disease mechanisms, based on molecular and genetic models, have paved the way for the development of novel experimental treatment options for GA that aim to cater to a thus far largely unmet need...
September 14, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28905243/3d-endothelial-cell-spheroid-human-vitreous-humor-assay-for-the-characterization-of-anti-angiogenic-inhibitors-for-the-treatment-of-proliferative-diabetic-retinopathy
#12
Sara Rezzola, Imtiaz M Nawaz, Anna Cancarini, Cosetta Ravelli, Stefano Calza, Francesco Semeraro, Marco Presta
Proliferative diabetic retinopathy (PDR) represents a main cause of acquired blindness. Despite the recognition of the key role exerted by vascular endothelial growth factor (VEGF) in the pathogenesis of PDR, limitations to anti-VEGF therapies do exist. Thus, rapid and cost-effective angiogenesis assays are crucial for the screening of anti-angiogenic drug candidates for PDR therapy. In this context, evaluation of the angiogenic potential of PDR vitreous fluid may represent a valuable tool for preclinical assessment of angiostatic molecules...
September 13, 2017: Angiogenesis
https://www.readbyqxmd.com/read/28902338/confluent-endpoint-subthreshold-argon-laser-for-serous-macular-detachment-in-tilted-disc-syndrome-refractory-to-anti-vegf
#13
Maria Fernanda Abalem, Pedro Carlos Carricondo, Helen Nazareth Veloso Dos Santos, Rafael Garcia, Cynthia X Qian, John Helal, Eduardo Cunha de Souza, Walter Yukihiko Takahashi
A 70-year-old woman presented with 20/200 visual acuity in the right eye. Multimodal imaging revealed tilted disc syndrome (TDS) with macular serous detachment (MSD) and pigmentary changes at the temporal margin of the optic disc. Subretinal fluid persisted after three monthly intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) injections and threshold focal laser photocoagulation. Subsequently, confluent subthreshold argon laser was applied over the entire area of retinal pigment epithelium (RPE) abnormalities, resulting in the resolution of subretinal fluid without recurrence through 3 years of follow-up...
September 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28902336/switching-anti-vegf-drugs-in-the-treatment-of-diabetic-macular-edema
#14
Touka Banaee, Mohammed Ashraf, Felipe F Conti, Rishi P Singh
Since their introduction in the late 2000s, anti-vascular endothelial growth factor (VEGF) agents have become the first-line choice for center-involved diabetic macular edema (DME). Even with its proven effectiveness, there are still cases that do not respond satisfactorily. In those cases, a treatment option is to change to another anti-VEGF drug. In this paper, the authors review studies on switching between different anti-VEGF drugs in the treatment of persistent DME. An extensive bibliographic review was done using PubMed, Embase, and Scopus...
September 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28900008/targeting-cxcr4-dependent-immunosuppressive-ly6c-low-monocytes-improves-antiangiogenic-therapy-in-colorectal-cancer
#15
Keehoon Jung, Takahiro Heishi, Joao Incio, Yuhui Huang, Elizabeth Y Beech, Matthias Pinter, William W Ho, Kosuke Kawaguchi, Nuh N Rahbari, Euiheon Chung, Jun Ki Kim, Jeffrey W Clark, Christopher G Willett, Seok Hyun Yun, Andrew D Luster, Timothy P Padera, Rakesh K Jain, Dai Fukumura
Antiangiogenic therapy with antibodies against VEGF (bevacizumab) or VEGFR2 (ramucirumab) has been proven efficacious in colorectal cancer (CRC) patients. However, the improvement in overall survival is modest and only in combination with chemotherapy. Thus, there is an urgent need to identify potential underlying mechanisms of resistance specific to antiangiogenic therapy and develop strategies to overcome them. Here we found that anti-VEGFR2 therapy up-regulates both C-X-C chemokine ligand 12 (CXCL12) and C-X-C chemokine receptor 4 (CXCR4) in orthotopic murine CRC models, including SL4 and CT26...
September 12, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28895632/-oct-angiography-in-exudative-amd-with-detachment-of-vascularised-retinal-pigment-epithelium
#16
Frederic Gunnemann, Kai Rothaus, Marie-Louise Farecki, Henrik Faatz, Benedikt Book, Albrecht Lommatzsch, Daniel Pauleikoff
Background The aim of the following extended case study was to analyse whether choroidal neovascularisation (CNV) in vascularised epithelial detachments (PED) in OCT angiography (OCT-A) can be better visualised in OCT-A than in the established angiographic methods during the course of anti-VEGF therapy and if possible used to quantify the CNV size and flow area. These findings were compared with other SD-OCT characteristics of the lesion (PED height, retinal thickness). Patients and Methods 8 patients with PED and associated CNV were diagnosed with multimodal imaging and additionally OCT angiography was performed...
September 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28895631/-oct-angiography-of-rpe-tears-in-exudative-amd-morpohological-analysis-of-the-choriocapillaris-and-the-rpe
#17
Matthias Gutfleisch, Kai Rothaus, Marie-Louise Farecki, Henrik Faatz, Britta Heimes-Bussmann, Frederic Gunnemann, Martin Ziegler, Ioannis Papapostolou, Albrecht Lommatzsch, Daniel Pauleikoff
Background Retinal pigment epithelium (RPE) tears are a typical complication of vascular pigment epithelium detachment in age-related macular degeneration (AMD). During proactive intense anti-VEGF therapy, stabilisation or improvement of function may occur. With the new method of OCT angiography (OCT-A), retinal vessels and flow density can be quantified. This pilot study investigates changes in the choriocapillars (CC) in areas with increasing FAF in OCT following an RPE-tear. Methods In six eyes with an RPE-tear, prospectively initially and every three months thereafter, multimodal imaging was performed, including fundus autofluorescence (FAF) (HRA2, Heidelberg Engineering, Heidelberg, Deutschland) and OCT-A (RTVue XR Avanti, SSDA-Modus, Angiovue, Optovue, Freemont, CA, USA)...
September 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28895630/-changes-in-oct-angiography-of-type-2-cnv-in-neovascular-amd-during-anti-vegf-treatment
#18
Henrik Faatz, Kai Rothaus, Frederic Gunnemann, Matthias Gutfleisch, Britta Heimes-Bussmann, Albrecht Lommatzsch, Daniel Pauleikoff, Marie-Louise Farecki
Purpose OCT-A is a new method to visualise the 2D and 3D structures of neovascular complexes in exudative AMD. The aim of the present study was to characterise type 2 CNV in different 2D segmentations and in 3D imaging and to investigate changes during anti-VEGF treatment. Methods 12 patients with type 2 CNV in FA and SD-OCT were selected. OCT-A (Avanti, Optovue) was obtained initially and after the first three injections and thereafter, if "new activity" (increase in sub- or intraretinal fluid) occurred...
September 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28893457/-treatment-of-choroidal-noevascularization-secondary-to-angioid-streaks-with-bevacizumab-and-response-experience-of-the-ophthalmology-department-of-hassan-ii-university-hospital
#19
M El Bahloul, F Chraïbi, S Aounzou, A Salam Diarra, M Abdellaoui, I Benatiya, H Tahri
PURPOSE: To evaluate the efficacy of intravitreal bevacizumab in the treatment of choroidal neovascularization (CNV) secondary to angioid streaks. METHODS: We conducted a prospective study in the ophthalmology department of Hassan II university hospital in Fez, including 12 eyes of 7 patients with CNV associated with angioid streaks. We injected 8 eyes with bevacizumab 1.25mg; best corrected visual acuity (BCVA), fundus examination, fluorescein angiography and optical coherence tomography were performed and analyzed for all patients before and after treatment...
September 8, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28886052/comparison-of-clinical-features-and-3-month-treatment-response-among-three-different-choroidal-thickness-groups-in-polypoidal-choroidal-vasculopathy
#20
Mingui Kong, Sung Min Kim, Don-Il Ham
Eyes with polypoidal choroidal vasculopathy (PCV) were recently reported to have various choroidal thickness, and choroidal thickness might be associated with visual outcome in the treatment of many retinal disorders. The range of subfoveal choroidal thickness (SFCT), clinical features, and 3-month treatment response among three groups having different range of SFCT were investigated in PCV eyes. In 78 treatment-naïve eyes with PCV, SFCT was measured using optical coherence tomography. Eyes were classified into thin, medium, and thick groups, using mean and one standard deviation of SFCT...
2017: PloS One
keyword
keyword
35594
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"